From: Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2
Diagnosis | Asymptomatic | SCD | ||
---|---|---|---|---|
Aß42/40 status | − | + | − | + |
N | 95 | 26 | 104 | 47 |
Age | 67.75 (4.76) | 69.35 (5.28) | 69.66 (5.9) | 72.21 (4.94) |
Sex (no. of females) | 37 | 17 | 57 | 29 |
Years of education | 14.42 (2.65) | 14.54 (2.87) | 15.08 (3.03) | 14.79 (3.04) |
Total tau | 338.97 (127.25) | 423.65 (158.77) | 293.97 (101.92) | 512.97 (224.9) |
Phosphotau181 | 46.80 (13.43) | 54.77 (18.58) | 44.72 (14.57) | 69.35 (30.5) |
Aß42/40 | 0.106 (0.0134) | 0.063 (0.014) | 0.11 (0.013) | 0.059 (0.012) |
MMSE | 29.4 (0.843) | 29.23 (1.03) | 29.09 (1.089) | 29.21 (1.14) |
PACC5 | 0.135 (0.514) | − 0.123 (0.801) | − 0.048 (0.626) | − 0.269 (0.683) |
ApoE 4 carrier status | 16% | 56% | 17% | 61.4% |